• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer
【24h】

The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer

机译：利用现实世界证据在乳腺癌中的口腔化疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Almost all patients with breast cancer will eventually receive chemotherapy drugs, the majority of which are administered as IV infusions. Real-world evidence indicates that while current treatment paradigms vary considerably from guideline recommendations, there is an increasing trend towards a preference for oral oncolytics among patients with breast cancer. Recent data have shown that oral anticancer therapeutics represent 25% of the oncology drug market share and that there is a high demand for these agents. Therefore, oral formulations of chemotherapy agents such as paclitaxel are currently under development. Although oral oncolytics are associated with several advantages over conventional intravenous drugs, maintaining adherence to therapy is a major barrier in achieving improved outcomes with these agents. Advanced practitioners can facilitate improved adherence to oral oncolytics by integrating evidence into practice to support better education and communication strategies to address patient concerns, overcome key hurdles, and ultimately, empower patients.
机译：几乎所有乳腺癌患者最终都会接受化疗药物，其中大部分是静脉注射。现实世界的证据表明，虽然目前的治疗模式与指南建议存在很大差异，但乳腺癌患者对口服抗肿瘤药物的偏好有增加的趋势。最近的数据显示，口服抗癌药物占肿瘤药物市场份额的25%，对这些药物的需求量很大。因此，紫杉醇等化疗药物的口服制剂目前正在开发中。尽管口服抗肿瘤药物与常规静脉注射药物相比具有一些优势，但维持治疗依从性是这些药物改善疗效的主要障碍。高级从业者可以通过将证据整合到实践中，支持更好的教育和沟通策略，以解决患者的问题，克服关键障碍，并最终增强患者的能力，从而促进对口腔抗肿瘤药物的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号